---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-045354"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:43:14.024271+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q3 rev $2.3M, cash burn $2.9M, reaffirms FY 2024 cash guidance

## Summary
- Q3 OvaSuite revenue $2.3M (+2% YoY); test volume 6,001 units (+4% YoY).
- OvaWatch volume grew 27% YoY, now 22% of total test volume.
- Cash used in ops $2.9M, down 12% from Q2; FY 2024 cash burn guidance reaffirmed $13.0-14.5M.
- Awarded $10M ARPA-H contract for ENDOinform; expects first $2M payment by year-end.
- Gross margin 60% (vs 59% YoY); sales & marketing up 26% but G&A down 25%.

## SEC filing metadata
- accession: 0001493152-24-045354
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000149315224045354/0001493152-24-045354-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000149315224045354/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-045354
- JSON: https://secwatch.observer/filing/0001493152-24-045354.json
- Plain text: https://secwatch.observer/filing/0001493152-24-045354.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.